...Faten Aqeel; Michael Joseph Cammarata; Dustin Le; Duvuru Geetha Introduction: Although an increased risk of Pneumocystis jirovecii pneumonia (PJP) has been reported in adults receiving rituximab for induction therapy, current evidence is lacking on the utility of PJP prophylaxis in ANCA-associated...

...Cláudia Costa; Amélia Antunes; João Oliveira; Marta Pereira; Iolanda Godinho; Paulo Fernandes; Sofia Jorge; José António Lopes; Joana Gameiro Introduction: Rituximab (RTX) has been reported as an effective treatment alternative in primary forms of minimal change disease (MCD) and focal segmental...

... the initial therapies, the steroid pulse was given to 13 (86.6%) patients, whereas membrane plasmapheresis was given to 8 (53.3%) patients. Inj. cyclophosphamide and inj. rituximab were given to 8 (53.3%) and 4 (26.6%) patients, respectively. No difference was seen in clinical characteristics, renal biopsy...

...Ahsan Aslam; Abbal Koirala Background: Minimal change disease and primary FSGS are podocytopathies but are also immune-mediated diseases. Rituximab acts via multiple mechanisms by tilting the balance between autoreactive B and T cells in favor of regulatory B and T cells. The consequences...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Glomerular disease Minimal change disease Glucocorticoids Nephrotic syndrome Immunosuppression Tacrolimus Rituximab...